The patent announcement for AXA1125, a treatment for long COVID fatigue, led to a significant surge in Axcella Health's stock. However, the stock pulled back the following day, indicating a potential short-term volatility. Despite the recent surge, the stock is still down significantly over a one-year period, which may indicate underlying issues.